<DOC>
	<DOC>NCT01783925</DOC>
	<brief_summary>The objective of this PMS is to gain information about safety and efficacy in real practice as a regulatory commitment required by MFDS</brief_summary>
	<brief_title>Eylea Post Marketing Surveillance(PMS)</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<criteria>Patients determined to start EYLEA treatment Patients who agree and sign informed consent Patients who receive EYLEA treatment for the first time Patients who meet one of the following Patients diagnosed by physician as having neovascular (wet) agerelated macular degeneration wAMD Patients diagnosed by physician as having visual impairment due to macular edema secondary to retinal vein occlusion (branch RVO or central RVO) Patients diagnosed as having visual impairment due to diabetic macular edema (DME) Patients diagnosed as having visual impairment due to myopic choroidal neovascularization (mCNV) Patients who have received antiVEGF therapy within 90 days Patients who are contraindicated based on the approved product label Ocular or periocular infection Active severe intraocular inflammation Known hypersensitivity to any ingredient of this drug</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>